Today: 20 May 2026
LSEG stock price today: shares slip in London after ICBC pact and fresh buyback details
30 January 2026
2 mins read

LSEG stock price today: shares slip in London after ICBC pact and fresh buyback details

London, January 30, 2026, 08:08 GMT — Regular session

  • LSEG shares slipped around 0.2% early Friday, following a 2.15% drop in the previous session
  • Company inked a strategic collaboration MoU with China’s ICBC
  • LSEG announced a new round of share buybacks, confirming the repurchased shares will be cancelled

Shares of London Stock Exchange Group (LSEG.L) slipped slightly in early Friday trading, as investors digested a fresh cooperation deal with China’s largest bank alongside new details on the group’s buyback plan. The stock hovered around 8,104 pence, down roughly 0.2%, after moving between 8,066 and 8,108 pence.

The news is significant as LSEG has relied on capital returns and partnerships to shore up sentiment following a tough stretch for its shares. Investors want reassurance that growth in its data, index, and clearing divisions can hold up amid pockets of softer trading activity and tight bank budgets.

A buyback, which means a company buying back its own shares, can boost earnings per share and suggest confidence. But if investors are focused on revenue growth instead, the market might not react positively.

LSEG announced it has signed a memorandum of understanding with Industrial and Commercial Bank of China (ICBC) to boost cooperation in financial markets, data and analytics, cross-border RMB, sustainable finance, and “financial innovation.” Fiona Bassett, CEO of FTSE Russell, said the partnership will “create new opportunities for issuers, investors and institutions worldwide.” ICBC vice president Zhang Weiwu highlighted efforts on “market connectivity and cross-border RMB development.” The MoU was finalized in Beijing on Jan. 29, coinciding with the UK prime minister’s visit to China, the company noted. LSEG

Separately, LSEG revealed it repurchased 223,295 shares on Jan. 29 at an average price of 8,246.46 pence each, with plans to cancel those shares. After the cancellation, the total voting rights will stand at 507,751,834—a key number investors watch to determine when disclosure thresholds under UK rules apply.

The stock is bouncing back after dropping 2.15% on Thursday to end at 8,118 pence, lagging behind a stronger FTSE 100 session. LSEG closed over 33% below its 52-week peak, with Thursday’s trading volume exceeding the 50-day average, according to MarketWatch data.

Traders now face a key question: will Friday’s announcements attract buyers or just temper the recent slide? The China partnership looks like a play for the long haul — focused on infrastructure and product connections — not a quick fix for next quarter’s results.

LSEG belongs to the same European group as Deutsche Börse and Euronext, firms that have expanded beyond cash equities into data, indices, and post-trade services. This diversification can stabilize revenues, but investors often see the shares as a gauge of market confidence and deal activity.

The ICBC deal serves as a framework rather than a finalized contract, meaning any commercial gains might be slow to materialize—or stall if UK-China ties worsen. Buybacks might soften declines but won’t fully offset any setbacks if upcoming earnings fall short on growth or expenses.

The next major event is LSEG’s preliminary results for the year ended Dec. 31, set for Feb. 26. Investors will focus on revenue trends, margin updates, and how quickly buybacks are progressing.

Stock Market Today

  • Parabilis Plans IPO to Fund Phase 3 Trial for Tumor Drug Following Regeneron Deal
    May 20, 2026, 5:56 AM EDT. Parabilis Medicines, a Massachusetts biotech, is preparing for an initial public offering (IPO) to finance the phase 3 trial of its tumor drug zolucatetide, targeting rare desmoid tumors. The drug, which inhibits the Wnt/β-catenin pathway implicated in many cancers, recently received FDA fast-track status. Proceeds will also support phase 1 trials for additional cancers. Parabilis secured a $50 million upfront payment and a $75 million equity investment from Regeneron in a deal to explore Parabilis' helicon peptide platform. The firm boasts over $300 million in cash from prior funding rounds. CEO Mathai Mammen aims to grow Parabilis into a fully integrated research, development, manufacturing, and commercialization company, relying on partnerships to finance its ambitions.

Latest articles

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

20 May 2026
OCI Energy and CPS Energy have begun building a 120-megawatt battery storage facility in southeastern Bexar County, aiming for commercial operation in 2027. The project follows a rise in average outage duration for CPS Energy customers to 75.38 minutes in 2025. OCI will own the facility, with CPS holding operational control. ING is financing construction, and LG Energy Solution Vertech is supplying batteries.
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

20 May 2026
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
Snowflake stock slides nearly 8% in software rout; traders brace for next catalyst
Previous Story

Snowflake stock slides nearly 8% in software rout; traders brace for next catalyst

GSK share price dips in London as Exdensur rollout and Feb 4 results loom
Next Story

GSK share price dips in London as Exdensur rollout and Feb 4 results loom

Go toTop